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At the time of expiry of patent protection for a given 
originator (reference) medicine, any manufacturer is free 
to market the said medicine as a generic medicine, under 
the conditions that it abides by Good Manufacturing Prac-
tice (GMP) and Good Clinical Practice (GCP)6–8 bearing 
in mind that adequate pharmaceutical and preclinical 
tests are provided and that bioequivalence of the generic 
medicine to the original medicine is proven by the manu-
facturer. Alongside the manufacturer marketing authori-
zation holder also has an important role in the authoriza-
tion procedure and post-marketing period of the medicine 
concerned. Some applicants, who don’t have appropriate 
bioequivalence studies for their generics, try to submit 
well-establish use application for the medicines concerned. 
This malpractice may raise important public health con-
Defi nition and price of generic medicine
Generic medicine is a medicinal product having the 
same qualitative and quantitative composition of active 
substances and the same pharmaceutical form as the ref-
erence medicinal product, and whose bioequivalence is 
proven to correspond with that of the reference medicine 
through bioavailability testing1,2. The same active sub-
stance is considered to be different salts, esters, ethers, 
isomers, mixtures of isomer, complexes or derivatives of 
the active substance, unless there are signifi cant differ-
ences in their properties with regard to the safety and/or 
effi cacy3–5. Various immediate-release oral pharmaceuti-
cal forms are considered to be the same pharmaceutical 
form.
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A B S T R A C T
A generic medicine is an equivalent of an originator pharmaceutical product. It contains the same active substance 
as, is »essentially similar« to, and is therefore interchangeable with, the originator product. The objective of this study was 
to determine the share of generic medicines of the total received marketing authorization applications in Croatia, and the 
specifi cities in the approval of generic medicines with regard to assessments of their quality documentation. We collected 
the information from the Agency’s medicinal products databases. Absolute numbers are shown for the applications for the 
authorizations of medicines in total and generics in particular in the period from 2005–2009. Data were analyzed using 
descriptive statistics. The annual number of marketing authorization applications for generic medicines received in 
Croatia increased from 148 applications in 2005 to 276 applications in 2009. In the period from 2005–2009, the number 
of applications for the approval of generic medicines accounted for 55% of all submitted applications. More than fi ve ge-
neric medicines were approved for the following active compounds: amlodipine, lisinopril, atorvastatin, tamsulosin and 
omeprazole. In the following years, the number of applications from international manufacturers stagnated, while the 
number of applications by local manufacturers is on a steady climb, with the exception of 2008. From 2005–2009, an 
almost continual increase in the number of applications for the approval of generic medicines is evident. The largest 
number of generic medicines was approved for generic medicines intended for the treatment of cardiovascular disease 
(amlodipine, lisinopril, atorvastatin). A continual increase of applications from local manufacturers has been recorded. 
In the approval of these medicines, it is very important to develop a uniform approach to assessing the quality of each 
medicine, in order to guarantee a high quality product for the patient.
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cerns, especially in the new Member States of EU which 
have to be particularly aware of this problem.
The reason why the price of generic medicines is less 
than the price of the originator medicine lies in the fact 
that generic medicines contain an active substance whose 
effi cacy and safety have already been established, not only 
in clinical trials prior to approval, but also in the many 
years of use in patients once it is marketed. Proven bio-
equivalence implies, at the present state of science, the 
same therapeutic value, so consequently, repetition of hu-
man trials is both scientifi cally unnecessary and unethi-
cal. The requirement for repeating experiments in hu-
mans for the purpose of proving facts that are already well 
known is contrary to the Helsinki Declaration on ethical 
principles in medical research conducted on humans9,10. 
Consequently, the procedure of approving generic medi-
cines is substantially shorter, and also requires substan-
tially less fi nancial investment by the manufacturer.
In all developed countries of the world, the legal regu-
lations are being amended in order to take better advan-
tage of generic medicines, which by defi nition should be 
less expensive than the originator medicine. In line with 
the above, the European Generic Medicines Association 
(EGA) lists a price reduction for generic medicines of 20– 
90% in comparison with the originator medicines11.
Data exclusivity period
Data Exclusivity Period is a period of time during 
which the applicant is restricted from applying to the 
medicines authorities for generic marketing authorization 
route, e.g. referring to the originator’s dossier and submit-
ting only bioequivalence study results. Consequently ge-
neric medicines can only be evaluated and approved by the 
medicines authorities after the data exclusivity period has 
expired. Data exclusivity guarantees additional market 
protection for originator pharmaceuticals by preventing 
health authorities from accepting applications for generic 
medicines during the exclusivity period.
The New EU Pharmaceutical Legislation adopted in 
2004 has created a harmonized EU eight-year data exclu-
sivity provision with an additional two-year market exclu-
sivity provision. This effective 10-year market exclusivity 
can be extended by an additional one year maximum if, 
during the fi rst eight years of those ten years, the market-
ing authorization holder obtains an authorizations for one 
or more new therapeutic indications which, during the 
scientifi c evaluation prior to their authorizations, are held 
to bring a signifi cant clinical benefi t in comparison with 
existing therapies. This is so called 8+2+1 formula which 
means that a generic application for marketing authoriza-
tion can be submitted after year 8, but that the product 
cannot be marketed until after year 10 or 1112–14.
U.S. law provides fi ve years of data exclusivity for new 
chemical entities, and three years for other pharmaceuti-
cal products13–15.
In Croatia, the data exclusivity period for a generic 
medicine is six years which is stipulated by the Act on 
Medicinal products; however, Amendments to the Act of 
200916, which regulate the period following the accession 
of Croatia to the EU, adopted the 8 + 2 + 1 formula17.
Approval of the generic medicine – necessary 
documentation for granting authorization
The application for marketing authorization of a ge-
neric medicine is accompanied by the documentation on 
the medicinal product in the form of the Common Techni-
cal Document (CTD). This documentation consists of fi ve 
basic parts (Modules), as depicted in Figure 1.
Given the known effi cacy and safety of the active sub-
stances, it is not necessary to append the results of con-
ducted non-clinical (Module 4) and clinical (Module 5) 
trial to the application for marketing authorization for a 
generic medicine. Instead of the complete Module 4 and 5 
documentation (Figure 1), for the majority of generic med-
icines, primarily those in solid oral forms, it is necessary 
to submit the results of in vivo bioavailability testing that 
confi rms the bioequivalence with the originator product 
(Module 5.3.1).
The quality of each medicine, including generic medi-
cines, must be specifi cally proven through comprehensive 
documentation which is assessed in detail by the regula-
tory authority prior to granting marketing authorization.
Assessment of the documentation on medicine 
quality
Medicine quality is a group of acceptable physicochem-
ical and biological properties of a medicine that is pro-
posed by the medicine manufacturer according to inter-




Module 2.1. CTD Table
of Contents (Module 2-5)
Module 2.2. CTD Introduction
Module 2.4 Module 2.5
Nonclinical       Clinical
Module 2.3 Overview Overview
Quality
Overall            Module 2.6        Module 2.7
Summary            Nonclinical         Clinical
Summary Summary
Module 3 Module 4 Module 5
Quality Nonclinical Clinical
study reports study reports
Fig. 1. Documentation on the medicinal product in the form
of the common technical document (schematic overview of the 
Common Technical Document (CTD) format). 
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European Directive19 and Scientifi c Guidelines on medi-
cine quality20 and guidelines of the International Confer-
ence on Harmonization (ICH)21).
Medicine quality is directly related to the quality of the 
starting materials (active substance, excipients, type of 
container), the production procedure that must be carried 
out in line with the rules of Good Manufacturing Practice 
(GMP) and the stability of the active substance and drug 
product that is ready for marketing.
The form and content of the documentation on medi-
cine quality (Module 3 – Quality) is precisely prescribed 
(in both Croatia and the European Union) and does not 
differ for originator and generic medicines. This documen-
tation consists of two main parts: data on active substance 
(Section 3.2.S) and data on the drug product (Section 
3.2.P). Each of these sections contains the stipulated chap-
ters with information that defi nes the quality of the active 
substances or the quality of the drug product.
With the previously stated differences in the documen-
tation necessary for marketing generic medicines, origina-
tor and generic medicines differ in the manufacturer of 
the active compounds, excipients, production procedure 
(technology) and selected container that is in direct con-
tact with the medicine (blister package, glass bottle, etc.). 
In the majority of cases, the manufacturer of the reference 
medicinal product is also the manufacturer of the active 
substance, while this is not the case with generic medi-
cines. Considering that different active substance manu-
facturers use different synthesis procedures, there are 
then differences in the quality requirements of generic 
medicines having the same active substances, and any 
assessment of quality thus requires a uniform approach 
with the application of the valid regulatory and scientifi c 
guidelines on medicine quality20.
The Croatian Agency for Medicinal Products and Med-
ical Devices (hereinafter: Agency) issues marketing au-
thorization for medicinal products pursuant to the Me-
dicinal Products Act2,16 and the accompanying Ordinance22. 
The Medicinal Products Act prescribes the basic require-
ments for granting marketing authorization for a medici-
nal product, the conditions for the production and sale of 
medicinal products, assessments of medicine quality, ad-
vertising and information about medicines, and the role 
and obligations of the Agency, while the accompanying 
Ordinance describes in detail the procedure of granting 
marketing authorization for medicinal products and the 
documentation required for granting authorization. In the 
marketing authorization procedure, the documents with 
important information on the medicine intended for health 
care workers (Summary of Product Characteristics) and 
patients (Patient Information Leafl et) and the medicine 
labeling are also approved.
Quality of active substances
For the purpose of determining the acceptability of the 
quality of active substances, the Agency for Medicinal 
Products and Medical Devices (hereinafter: Agency) is 
permitted further insight into the section of the documen-
tation on the active substance, with detailed information 
on the starting materials in the synthesis of active sub-
stances, and the production procedures in the synthesis of 
active substances. In the majority of cases, the manufac-
turer of the generic medicine does not have insight into 
these “restricted” data, except in cases when the manu-
facturer of the active compound is also the manufacturer 
of the drug product.
In assessing the quality of active substances, it is im-
portant to differentiate the active substances described in 
the European Pharmacopoeia (Ph.Eur.) or other world 
Pharmacopoeia from those not described in the European 
Pharmacopoeia. Considering that Pharmacopoeia mono-
graphs defi ne a certain standard of quality, the use of 
these substances ensures the same/equivalent quality of 
active substances, thereby greatly facilitating the quality 
assessment. Also, certifi cate of suitability (CEP) issued by 
EDQM (European Directorate for the Quality of Medi-
cines & HealthCare) is usually used by the manufacturers 
of pharmaceutical products in their marketing authoriza-
tion applications to demonstrate the compliance of the ac-
tive substance used with the monograph of the European 
Pharmacopoeia. This CEP procedure is aimed at facilitat-
ing and simplifying exchanges between all partners (drug 
substance manufacturer, drug product manufacturer and 
authorities) to ensure that the quality of substances is 
guaranteed. On the other hand, in the quality assessment 
of active substances not described in the Pharmacopoeia, 
it is necessary to use the more general Guidelines that are 
valid in the European Union20 with instructions on accept-
able criteria for the quality of active substances. There-
fore, conducting an assessment on the quality of such ac-
tive substances is much more complex and requires more 
experience and time.
Quality of drug products
The assessment of data on the quality of drug products 
is even more complex, as in addition to the shown proper-
ties of the active substance, it is necessary to also con-
sider other factors that can directly infl uence drug qual-
ity. Special attention is directed at the selection of 
excipients and their compatibility with the active sub-
stances, appropriateness of the selected and implemented 
the production procedures and stability of the drug prod-
uct in the selected container. Considering that the Euro-
pean Pharmacopoeia lists only the general requirements 
that certain pharmaceutical forms of drug product must 
comply with, and does not prescribe monographs for indi-
vidual medicines, the valid Guidelines in the European 
Union21 are applied in the assessment of drug product 
quality. The monographs of individual drug product de-
scribed in other Pharmacopoeia (United States Pharma-
copoeia/USP23, British Pharmacopoeia/BP24) can also be 
used; however, they serve only as an aid in forming the 
opinion on the quality of the drug product.
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Methods
Data were collected from the Agency’s medicinal prod-
ucts databases. Absolute numbers are shown for the ap-
plications for marketing authorizations for medicinal 
products in total as well as for generic medicinal products 
in particular for the period from 2005–2009. Data were 
analyzed using descriptive statistics. Additionally, we 
analyzed the Anatomical Ther apeutic Chemical (ATC) 
Classifi cation of medicines whose applications were sub-
mitted to the Agency in 2009.
Results
Applications for marketing authorization for 
medicinal products in the Republic of Croatia
Figure 2 shows the number of applications for market-
ing authorizations for medicinal products in Croatia sub-
mitted to the Agency in the period 2005–2009. The shown 
number of applications includes the number of received 
applications for granting marketing authorization, includ-
ing all doses and pharmaceutical forms of the same med-
icine. From the above, it is clear that the total number of 
applications for marketing authorizations in 2009 was al-
most twice the number of applications submitted in 2005.
Figure 3 shows the number of applications for market-
ing authorization in 2009 by individual organic systems 
(from A to V) according to the Anatomical Therapeutic 
Chemical (ATC) Classifi cation of Medicines. The number 
of applications shown includes the total number of received 
applications for marketing authorization, including all 
doses and pharmaceutical forms of the same medicine. 
From the above, it is clear that the number of applications 
for approval submitted in 2009, the majority pertain to 
medicines acting on the cardiovascular system (C/17%) 
and nervous system (N/17%). These are followed by anti-
neoplastic and immunomodulatig agents (L/13%), anti-
infectives for systematic use (J/12%) and medicines acting 
on the alimentary tract and metabolism (A/12%). This 
division by organic system largely corresponds to the divi-
sion within the EU Member States25.
Figure 4 shows the share of applications for marketing 
authorization for generic medicines in comparison to the 
originator medicine, and all other applications that can 
further be divided into medicines with well established 
use, over-the-counter medicines, herbal medicines, homeo-
pathic products, etc. in the period from 2005 to 2009. 
From the fi gure, it is evident that the number of market-
ing authorization applications for generic medicines ac-
counts for 55% of all submitted applications in this period.
Figure 5 shows the annual number of applications for 
marketing authorization of generic medicines from 2005 
to 2009. A continual increase of the total number of mar-
keting authorizations for generic medicines was recorded 
in this period, with the highest increase in 2006. The rea-
son why 2006 does not follow this trend is that in 2006, 
the accelerated application procedure was introduced for 
medicines approved in the EU (through the Ordinance on 
special conditions for marketing medicinal products in the 
Republic of Croatia having marketing authorization in the 
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Fig. 2. Annual number of applications for marketing authoriza-
tion for medicinal products in Croatia from 2005 to 2009.
Fig. 3. Share of applications for marketing authorization in Croatia in 2009 according to the Anatomical Therapeutic Chemical 
(ATC) classifi cation.
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a signifi cant jump in the number of applications received 
for medicinal product approvals were recorded (Figure 2). 
The same trend was noted also for the approval of generic 
medicines (Figure 5).
Figure 6 shows the marketing authorization applica-
tion for generic medicines submitted by manufacturers 
seated in Croatia (hereinafter: local manufacturers) and 
those seated outside of Croatia (hereinafter: international 
manufacturers). Manufacturers seated in Croatia carry 
out the comprehensive product procedure or individual 
phases of medicine production pursuant to the Medicinal 
Products Act. These are most often the phases of packing 
and quality control of a medicinal product from another 
manufacturer, with the obligation of releasing individual 
batches of medicines onto the Croatian market. The fi gure 
indicates virtually continuous growth in the number of 
marketing authorization applications for generic medi-
cines by local manufacturers (with the exception of 2008). 
The number of applications by international manufactur-
ers generally stagnated (with the exception of 2006 and 
2007).
In an overview of the authorizations granted for ge-
neric medicines by local manufacturers and international 
manufacturers, it is evident that more than fi ve generic 
medicines have thus far been approved for certain active 
substances in the Republic of Croatia (amlodipine, lisino-
pril, atorvastatin, tamsulosin, omeprazole, clopidogrel and 
pantoprazole), as shown in Table 1.
The table shows that there are a large number of med-
icines by local manufacturers for the said active com-
pounds that are most prescribed in Croatia (with the ex-
ception of tamsulosin as a newer active substance). 
Namely, the business policy of local manufacturers is 
based on the need for offering as many of the most com-
monly prescribed medicines as possible, in order to ensure 
regular supply of these medicines to the local market 
through the health care system. On the other hand, each 
newly approved medicine with the same active substance 
lowers the price on the Croatian market, which in turn 
reduces the interest of international manufacturers for 
submitting applications for active compounds which are 
already in use in large numbers in the Republic of Croatia. 
For that reason, the interest of international manufactur-
ers is more directed at obtaining authorization for newer 
generic medicines which have not yet been represented on 
the Croatian market, or have been represented in fewer 
numbers.
Specifi cities in the approval of generic medicines 
with regard to assessments of their quality docu-
mentation (shown on the example of atorvastatin)
Finally, we analyzed examples of approved quality ap-















































































Fig. 4. Share of applications for authorizations for generic 
medicines in comparison to other applications in Croatia from 
2005 to 2009.
Fig. 5. Annual number of marketing authorization applications 
for generic medicines in the Republic of Croatia in the period 
from 2005 to 2009.
Fig. 6. Annual number of marketing authorization applications 
for generic medicines by local manufacturers in comparison 
with international manufacturers.
TABLE 1
OVERVIEW OF SEVERAL APPROVED GENERIC MEDICINES 







Amlodipine 5 3 8 C08CA
Lisinopril 5 2 7 C09AA
Omeprazole 5 2 7 A02BC
Tamsulosin 2 4 6 G04CA
Atorvastatin 4 2 6 C10AA
Clopidogrel 4 1 5 B01AC
Pantoprazole 4 1 5 A02BC
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generic medicines containing atorvastatin from different 
manufacturers. The active compound atorvastatin is not 
described in the European Pharmacopoeia. As previously 
mentioned, several medicines with atorvastatin have al-
ready been approved for use in Croatia, of which one is the 
originator medicine, six are generic medicines and one is 
a combination of atorvastatin and other active substances 
(total of eight medicines). These medicines are produced 
by seven manufacturers (including three from Croatia) 
using atorvastatin as active substance from fi ve manu-
facturers with different synthesis procedures in their pro-
duction. Therefore, the active substance used differs in 
possible impurities, physicochemical properties (polymor-
phism, solubility, and release from the solid pharmaceuti-
cal form) and stability. This is the reason why for these 
medicines, the manufacturers propose signifi cantly differ-
ent quality requirements, especially with regard to impu-
rities, as shown in Table 2. In examples A and C, there are 
clear differences in the permitted levels for individual/
group impurities that the medicine must comply with 
prior to marketing (at release) or during the proposed va-
lidity period of the medicine (shelf life).
Discussion
Applications for marketing authorization for 
medicinal products in the Republic of Croatia
Following establishment of the Agency in late 2003, 
the marketing authorization granting procedure was uni-
fi ed, thereby greatly simplifying and accelerating the au-
thorization procedure in Croatia. Previously, the assess-
ment of the pharmaceutical documentations on medicine 
quality was carried out by the Croatian Institute for Med-
icine Control and the Croatian Institute for the Control of 
Immunobiological Medicines, while the Ministry of Health 
and Social Welfare conducted assessments of non-clinical 
and clinical documentation on medicines for the granting 
of marketing authorization. In addition to this change to 
the authorization procedure, the further development of 
the pharmaceutical industry in the new global economic 
and regional political circumstances fostered a signifi cant 
increase in applications.
According to available information, the signifi cant in-
crease in the number of applications for granting market-
ing authorization for generic medicines in the period from 
2005 to 2009 is tied to the expiry of patent protection of a 
large number of reference medicine products. According 
to the submitted marketing authorization applications, it 
was also observed that a large number of applications was 
submitted by multiple applicants for the same medicine, 
under a different name, but based on the same medicinal 
product documentation, which lead to a further increase 
in the number of applications submitted for the same 
medicines. In this way, the majority of generic medicine 
manufacturers also use, in addition to their own develop-
ment, the possibility of submitting marketing authoriza-
tion applications based on the medicinal product documen-
tation of another owner or manufacturer that developed 
the medicine.
The growing trend in the number of applications for the 
approval of generic medicines observed in this period re-
sulted in the fact that the share of applications for ge-
neric medicines surpassed the number of requests for 
originator and other medicines. This share was 55%, and 
it is expected that it will continue to grow in line with the 
growing trend of the number of generic medicines avail-
able in Europe and the world27–29.
While examining the seat of the manufacturers of ge-
neric medicines, during the observed period, the number 
of applications by international manufacturers stagnated 
(with the exception of 2006 and 2007). As previously men-
tioned, 2006 differed from all other years due to the intro-
duction of the accelerated application and approval proce-
dure for medicines already approved in the EU (made 
possible with the coming into effect of the Ordinance on 
special conditions for marketing medicinal products in the 
Republic of Croatia having marketing authorization in the 
European Union Member States26), which benefi ted inter-
national manufacturers. Therefore, a signifi cant jump in 
the number of applications submitted for all medicine ap-
provals (Figure 2) and a jump in the number of applica-
tions for the approval of generic medicines (Figure 5) have 
TABLE 2
EXAMPLES OF PERMITTED LIMITS FOR IMPURITIES/





     – impurity 1 max. 0.2% max. 0.3%
    – impurity 2 max. 0.5% max. 0.7%
    – impurity 3 max. 0.6% max. 2.0%
    – impurity 4 and impurity 5 max. 0.9% max. 2.5%
    – impurity 6 max. 0.4% max. 0.6%
    – greatest unknown impurity max. 0.2% max. 0.2%




    – impurity 1 max. 0.3% max. 0.3%
    – impurity 3   max. 0.25%   max. 0.25%
    – impurity 7 max. 0.3% max. 0.3% 
    – impurity 8 max. 0.5% max. 0.5%
    – impurity 9 max. 0.7% max. 0.7% 
    – impurity 10 max. 0.3% max. 0.3%
    – other individual impurities max. 0.2% max. 0.2%




    – individual impurity max. 0.5%
    – known individual impurity max. 1.5% 
    – other individual impurity max. 1.0%
    – total impurities max. 2.0% max. 5.0%
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been seen. Of these, the majority were those produced by 
international manufacturers, as the said Ordinance short-
ened the approval procedure for medicinal products al-
ready approved in the EU. After this jump in the number 
of applications for the approval of generic medicines by 
international manufacturers in 2006, a logical drop in the 
number of applications followed in 2007.
On the other hand, the number of applications of local 
manufacturers has been on a constant climb in the ob-
served period, with the exception of 2008. In 2007 and 
2009, the number of applications submitted by local man-
ufacturers exceeded the number submitted by interna-
tional manufacturers. The increasing number of applica-
tions from local manufacturers lies in the fact that new 
manufacturers of generic medicines are constantly being 
established in the territory of the Republic of Croatia.
It was also observed that more than fi ve generic medi-
cines were approved for the following active compounds: 
amlodipine, lisinopril, atorvastatin, tamsulosin and 
omeprazole. These are primarily medicines for the cardio-
vascular system (amlodipine, lisinopril atorvastatin), as 
the largest number of applications are submitted for these 
medicines in general (Figure 3).
Specifi cities in the approval of generic 
medicines with regard to assessments of 
their quality documentation
In the examination of the medicine quality documenta-
tion, it was noted that several shortcomings commonly 
occur. The most common is the non-compliance of the data 
in individual sections of the documentation, non-compli-
ance with the valid quality guidelines, improperly con-
ducted and documented development of the medicine for-
mulation, and lack of data on the active substance.
In accordance with the Ordinance in effect in Croatia, 
the quality of the active substance must comply with the 
requirements of the Ph.Eur. and the manufacturer is 
obliged to declare according to this Pharmacopeia. Only 
in the case if the active substance is not described in the 
Ph.Eur. the requirements of other Pharmacopeia may be 
accepted as quality standards, and thus the most common 
shortcoming in the documentation is the declaration of the 
quality of the active substance according to another Phar-
macopoeia (USP, JP) despite also being described in the 
Ph.Eur. while referring to BP is acceptable because BP 
follows the EP for active substance.
Another common deviation was seen in the general 
quality requirements for individual pharmaceutical forms 
prescribed in the Ph.Eur. (i.e. requirement for the release 
of active substance, uniformity of dosage units) and the 
lack of testing important for individual pharmaceutical 
forms (i.e. testing the sub-visible particles in parenteral 
solutions). It is also common that the manufacturer did 
not conduct stability testing of the medicine in line with 
the valid ICH guidelines (testing protocol, number of test-
ed series, availability of results, etc.), or did not prescribe 
the validity period of the medicine and storage conditions, 
in line with the valid ICH guidelines.
To present an example of differences in medicine qual-
ity specifi cations we showed possible impurities/degrada-
tion products in three medicines products with atorvas-
tatin (Table 2). Two presented examples (A and B) 
illustrate requirements in line with the valid quality 
guidelines20 that stipulate the criteria for setting and ac-
cepting permitted limits for possible impurities/degrada-
tion products in the medicinal product. Differences in 
impurity requirements in examples A, B and C are due to 
different polymorphic form of active substance that show 
different stability which consequently affect the stability 
of drug product. Specifi cation of drug product with more 
stable polymorphic form of drug substance (example B) is 
confi rmed with stability results. Differences in the speci-
fi cations for release and shelf life in examples A and C are 
caused by less stable polymorphic form of active substance 
(it is evident from the stability results). In order to accept 
the requirement from example A, the manufacturer must 
conduct further qualifi cation and toxicological testing of 
such an atorvastatin due to the greater quantity of indi-
vidual and total impurities, in order to confi rm the safety 
(which is in line with ICH Guideline Q3B(R2) Impurities 
in New Drug Products which describe the principle of the 
requirements to indicate, identify or toxicologically qual-
ify the contaminants). Considering the quality require-
ments, example C does not meet the valid quality guide-
lines, and pertains to a medicine that has long been 
marketed, this application needs to be renewed / harmo-
nized through upgrade documentation.
Table 2 also clearly shows that there are signifi cant 
differences in the quality documentation of generic medi-
cines, which could additionally suggest the differences in 
the quality of these medicines. Only those medicines with 
proven quality are allowed to be marketed. Their quality 
can be proven in the comprehensive medicinal product 
documentation, based on laboratory testing.
Conclusions
From 2005 to 2009, a growing trend was evident in the 
number of applications for the approval of generic medi-
cines, and among the active substance for which the ma-
jority of generic medicines were approved; most were in-
tended for the treatment of cardiovascular diseases 
(amlodipine, lisinopril, atorvastatin). This is in line with 
the Western European trends, as the consumption of these 
medicines for the treatment of chronic cardiovascular dis-
eases is signifi cant, making these medicines interesting 
for medicine manufacturers. In general, it can be conclud-
ed that the production of generic medicines is interesting 
to manufacturers, as they take a high share on the market 
owing to their lower prices.
Virtually constant growth has been recorded in the 
applications of local manufacturers, and these have sur-
passed the number of applications by international manu-
facturers in recent years. The growth in the number of 
applications from local manufacturers lies in the fact that 
new generic medicine manufacturers are continuously be-
ing established in Croatian territory. The continuation of 
this trend is also expected in the future, due to the an-
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nouncement of new generic medicine manufacturers in 
Croatia.
In the approval of generic medicines, special attention 
must be paid to the quality of generic medicines, and to 
ensure that only those medicines whose quality is guar-
anteed pursuant to comprehensive medicinal product 
documentation and laboratory testing can be marketed. It 
is important to develop a uniform, systematic and compre-
hensive approach to assessing medicine quality, in order 
to guarantee high quality products for patients. Therefore, 
the regulatory body has an important task in the assess-
ment and approval of these medicines.
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GENERIČKI LIJEKOVI U HRVATSKOJ – REGULATORNI ASPEKTI I STATISTIKA
S A Ž E T A K
Generički lijek je lijek ekvivalentan referentnom lijeku. Sadrži istu djelatnu tvar kao referentni lijek, »esencijalno je 
sličan« referentnom lijeku te stoga može zamijeniti referentni lijek. Svrha ovog istraživanja je odrediti koliki se udio od 
ukupno zaprimljenih zahtjeva za odobravanje lijekova u RH odnosi na generičke lijekove, kao i specifi čnosti u odobra-
vanju generičkih lijekova vezane uz ocjenu dokumentacije o njegovoj kakvoći. Također proučeno je dolaze li proizvođači 
generičkih lijekova prvenstveno iz Hrvatske ili inozemstva te za koje djelatne tvari postoji više od 5 odobrenih generičkih 
paralela (lijekova) u Hrvatskoj. Prikupljeni su podaci iz baze lijekova Agencije za lijekove i medicinske proizvode. Pri-
kazani su absolutni brojevi zaprimljenih zahtjeva za dobivanje odobrenja za lijekove općenito te posebno za generičke 
lijekove u periodu od 2005.–2009. godine. Podaci su analizirani deskriptivnom statistikom. Godišnji broj zahtjeva za 
odobravanje generičkih lijekova u RH je narastao sa 148 u 2005. godini na 276 zahtjeva u 2009.g. Odnosno, u razdoblju 
od 2005. do 2009. godine, broj zahtjeva za odobravanje generičkih lijekova čini 55% ukupno podnesenih zahtjeva. Za 
sljedeće djelatne tvari je odobreno više od 5 generičkih lijekova: amlodipin, lizinopril, atorvastatin, tamsulozin i omepra-
zol. U narednim godinama broj zahtjeva stranih proizvođača u pravilu stagnira dok je broj zahtjeva domaćih proizvođača 
u stalnom porastu (uz izuzetak 2008.g.). Od 2005.g. do 2009.g. vidljiv je gotovo kontinuiran porast ukupnog broja 
zahtjeva za odobravanje generičkih lijekova, a među djelatnim tvarima za koje je odobren najveći broj generičkih li-
jekova prevladavaju one koje su namijenjene liječenju kardiovaskularnih bolesti (amlodipin, lizinopril, atorvastatin). 
Zabilježen je gotovo stalan porast zahtjeva domaćih proizvođača što se očekuje i u budućnosti zbog najave novih proizvođači 
generičkih lijekova u Hrvatskoj. Kod odobravanja ovih lijekova važno je razviti jedinstven pristup ocjene kakvoće svak-
og lijeka kako bi se jamčio kvalitetan proizvod za pacijenta.
